Alvotech - Ordinary Shares (ALVO)
ALVO moved a median of 0.00% 30 minutes after news, and -0.18% by the close. How ALVO actually reacts to news — the realized, point-in-time move the market made, measured across 591 labeled events over the last three years with zero look-ahead.
ALVO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 574 |
| 30-min | 0.00% | 45% | 586 |
| 60-min | -0.09% | 46% | 588 |
| to close | -0.18% | 46% | 577 |
| Middle 50% of ALVO reactions | -0.92% to +0.89% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 591 |
Half of all Alvotech - Ordinary Shares news events land between -0.92% and +0.89% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ALVO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 22 | +0.89% | 73% | +1.67% |
| Analyst downgrades | 10 | -0.10% | 20% | -0.09% |
| Coverage initiations | 12 | +0.62% | 67% | +0.71% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ALVO ranks against every other measured name →
That’s how ALVO usually reacts — get an email when it moves on news →Email me when ALVO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ALVO's baseline. Nothing else.
Recent ALVO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg | Press release | GlobeNewswire | +1.79% | -2.82% | |
| Form 6-K Alvotech For: Oct 14 | SEC filing · Form 6-K | SEC EDGAR | -0.74% | -4.26% | |
| Form 6-K Alvotech For: Oct 06 | SEC filing · Form 6-K | SEC EDGAR | -0.17% | -2.90% | |
| FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® | Press release | GlobeNewswire | +5.59% | +3.56% | |
| Form 6-K Alvotech For: Oct 05 | SEC filing · Form 6-K | SEC EDGAR | +5.59% | +3.56% | |
| Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations | Press release | GlobeNewswire | +1.20% | +3.80% | |
| Form 6-K Alvotech For: Aug 31 | SEC filing · Form 6-K | SEC EDGAR | +1.20% | +3.80% | |
| Form 6-K Alvotech For: Aug 21 | SEC filing · Form 6-K | SEC EDGAR | +0.45% | +0.45% | |
| Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update | Press release | GlobeNewswire | +0.00% | +9.77% | |
| Form 6-K Alvotech For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +9.77% | |
| Alvotech announces successful closure of FDA inspection of manufacturing facility | Press release | GlobeNewswire | +2.43% | +14.24% | |
| Form 6-K Alvotech For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | -0.28% | +0.00% | |
| Form 6-K Alvotech For: Jul 01 | SEC filing · Form 6-K | SEC EDGAR | +0.27% | -5.04% | |
| Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares | Press release | GlobeNewswire | +1.91% | +0.00% | |
| Form 6-K Alvotech For: Jun 18 | SEC filing · Form 6-K | SEC EDGAR | — | +1.16% | |
| Form 6-K Alvotech For: Jun 16 | SEC filing · Form 6-K | SEC EDGAR | +0.29% | +1.69% | |
| Form 6-K Alvotech For: Jun 15 | SEC filing · Form 6-K | SEC EDGAR | -1.93% | -0.26% | |
| Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio® | Press release | GlobeNewswire | +2.07% | +17.13% | |
| Form 6-K Alvotech For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +5.30% | -4.15% | |
| Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea® | Press release | GlobeNewswire | +0.64% | +18.73% | |
| Form 6-K Alvotech For: Jun 04 | SEC filing · Form 6-K | SEC EDGAR | +0.64% | +18.73% | |
| Form 6-K Alvotech For: May 11 | SEC filing · Form 6-K | SEC EDGAR | +0.29% | +5.28% | |
| Form 6-K Alvotech For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +2.02% | +1.44% | |
| Form 20-F Alvotech For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -1.80% | +3.00% | |
| Alvotech Files Annual Report with the SEC | Press release | GlobeNewswire | -1.80% | +3.00% | |
| Form 6-K Alvotech For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | -3.00% | -2.19% | |
| Alvotech Q4 2025 and Full Year 2025 Financial Results | Press release | GlobeNewswire | -3.00% | -2.19% | |
| Form 6-K Alvotech For: Feb 27 | SEC filing · Form 6-K | SEC EDGAR | -2.16% | -4.09% | |
| Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® | Press release | GlobeNewswire | +1.36% | -3.11% | |
| Form 6-K Alvotech For: Feb 05 | SEC filing · Form 6-K | SEC EDGAR | +1.36% | -3.11% | |
| Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates | Press release | GlobeNewswire | -0.19% | -0.19% | |
| Form 6-K Alvotech For: Feb 02 | SEC filing · Form 6-K | SEC EDGAR | -0.19% | -0.19% | |
| Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg | Press release | GlobeNewswire | +1.58% | +0.93% | |
| Form 6-K Alvotech For: Jan 29 | SEC filing · Form 6-K | SEC EDGAR | +1.58% | +0.93% | |
| Form 6-K Alvotech For: Jan 06 | SEC filing · Form 6-K | SEC EDGAR | -0.43% | +0.87% | |
| Form 6-K Alvotech For: Jan 07 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.72% | |
| Alvotech announces planned CEO succession and leadership transition | Press release | GlobeNewswire | +0.42% | -4.38% | |
| Form 6-K Alvotech For: Jan 06 | SEC filing · Form 6-K | SEC EDGAR | +0.66% | +0.22% | |
| Form 6-K Alvotech For: Dec 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 6-K Alvotech For: Dec 22 | SEC filing · Form 6-K | SEC EDGAR | +1.86% | +9.07% | |
| Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma | Press release | GlobeNewswire | +1.54% | +0.61% | |
| Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® | Press release | GlobeNewswire | +4.27% | +2.08% | |
| Form 6-K Alvotech For: Dec 19 | SEC filing · Form 6-K | SEC EDGAR | -0.61% | +0.10% | |
| Form 6-K Alvotech For: Dec 17 | SEC filing · Form 6-K | SEC EDGAR | +0.40% | +0.60% | |
| Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area | Press release | GlobeNewswire | -1.36% | +6.21% | |
| Form 6-K Alvotech For: Nov 24 | SEC filing · Form 6-K | SEC EDGAR | +0.57% | +4.89% | |
| Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab) | Press release | GlobeNewswire | +0.19% | -6.12% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Alvotech (ALVO) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.34% | -4.31% | |
| Form 6-K Alvotech For: Nov 20 | SEC filing · Form 6-K | SEC EDGAR | +0.19% | -6.12% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Alvotech (ALVO) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.29% | +0.87% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ALVO section they belong to.
Where else ALVO is measured.
ALVO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alvotech - Ordinary Shares's median reaction calculated?
Every labeled ALVO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 591 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of ALVO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ALVO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.